Charles River Laboratories International (CRL) to Release Earnings on Thursday

Charles River Laboratories International (NYSE:CRL) is expected to be posting its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Charles River Laboratories International to post earnings of $1.96 per share and revenue of $977.4560 million for the quarter. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06. The firm had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The company’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the company earned $2.66 EPS. On average, analysts expect Charles River Laboratories International to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Charles River Laboratories International Stock Up 3.8%

NYSE CRL opened at $172.10 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29. The company has a market capitalization of $8.49 billion, a P/E ratio of -58.14, a P/E/G ratio of 2.01 and a beta of 1.44. Charles River Laboratories International has a one year low of $113.89 and a one year high of $228.88. The stock has a 50 day moving average price of $169.78 and a 200-day moving average price of $183.17.

Institutional Trading of Charles River Laboratories International

Several institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its stake in Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after purchasing an additional 1,446,972 shares during the last quarter. State Street Corp lifted its stake in Charles River Laboratories International by 2.2% in the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after purchasing an additional 40,535 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Charles River Laboratories International by 27.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,442,224 shares of the medical research company’s stock worth $287,703,000 after purchasing an additional 311,319 shares during the last quarter. Bank of America Corp DE lifted its stake in Charles River Laboratories International by 13.4% in the third quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock worth $182,017,000 after purchasing an additional 137,335 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Charles River Laboratories International by 33.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 769,437 shares of the medical research company’s stock valued at $120,386,000 after acquiring an additional 190,828 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on CRL shares. Wall Street Zen lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. Robert W. Baird set a $193.00 price target on Charles River Laboratories International in a research report on Thursday, February 19th. Royal Bank Of Canada started coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price target for the company. Finally, Barclays lifted their price target on Charles River Laboratories International from $200.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 14th. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and a consensus price target of $205.36.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.